Trial Outcomes & Findings for Contrast Volume Reduction During PCI With the Use of a New Assisting Software Package (NCT NCT02927990)

NCT ID: NCT02927990

Last Updated: 2024-12-06

Results Overview

Phase 2 not initiated Only phase 1 data was collected

Recruitment status

TERMINATED

Target enrollment

80 participants

Primary outcome timeframe

Amount of contrast [mL] will be determined once, at the end of the Percutaneous Coronary Intervention. There is no patient follow-up.

Results posted on

2024-12-06

Participant Flow

80 subjects are enrolled. Phase 2 not initiated.

Participant milestones

Participant milestones
Measure
Subject Undergoing PCI Phase 1
Subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
Overall Study
STARTED
80
Overall Study
COMPLETED
24
Overall Study
NOT COMPLETED
56

Reasons for withdrawal

Reasons for withdrawal
Measure
Subject Undergoing PCI Phase 1
Subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
Overall Study
Protocol Violation
4
Overall Study
Physician Decision
9
Overall Study
Room switched and therefore no study device available
15
Overall Study
No procedure performed, only diagnostic catheterization
28

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Subject Undergoing PCI Phase 1
n=24 Participants
Subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
Age, Continuous
67.9 years
STANDARD_DEVIATION 6.4 • n=24 Participants
Sex: Female, Male
Female
5 Participants
n=24 Participants
Sex: Female, Male
Male
19 Participants
n=24 Participants
Region of Enrollment
United States
24 participants
n=24 Participants
BMI
27.8 kg/m^2
STANDARD_DEVIATION 3.9 • n=24 Participants

PRIMARY outcome

Timeframe: Amount of contrast [mL] will be determined once, at the end of the Percutaneous Coronary Intervention. There is no patient follow-up.

Population: No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

Phase 2 not initiated Only phase 1 data was collected

Outcome measures

Outcome measures
Measure
PCI Phase 1
n=23 Participants
Phase 1 subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
PCI Phase 2
Not initiated.
Amount [mL] of Contrast Used for Completion of the Coronary Intervention
210 mL
Standard Deviation 108.77

SECONDARY outcome

Timeframe: DAP [mGycm^2] will be determined once, at the end of the Percutaneous Coronary Intervention. There is no patient follow-up.

Population: No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

Outcome measures

Outcome measures
Measure
PCI Phase 1
n=22 Participants
Phase 1 subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
PCI Phase 2
Not initiated.
Cumulative Dose Area Product (DAP) of Percutaneous Coronary Intervention
116409 mGy*cm^2
Standard Deviation 118360

SECONDARY outcome

Timeframe: AK [mGy] will be determined once, at the end of the Percutaneous Coronary Intervention. There is no patient follow-up.

Population: No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

Outcome measures

Outcome measures
Measure
PCI Phase 1
n=24 Participants
Phase 1 subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
PCI Phase 2
Not initiated.
Cumulative Air-Kerma (AK) of Percutaneous Coronary Intervention
1154 mGy
Standard Deviation 1022

SECONDARY outcome

Timeframe: Fluoroscopy time [minutes] will be determined once, at the end of the Percutaneous Coronary Intervention. There is no patient follow-up.

Population: No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

Outcome measures

Outcome measures
Measure
PCI Phase 1
n=24 Participants
Phase 1 subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
PCI Phase 2
Not initiated.
Total Fluoroscopy Time of Percutaneous Coronary Intervention
22 minutes
Standard Deviation 28.37

SECONDARY outcome

Timeframe: Patients will be followed from start of interventional procedure (vascular access obtained) until end of the procedure (vascular closure), ranging between 30 minutes and a few hours.

Population: No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

The endpoint is procedural timing: * time from start of procedure (wire introduced into the coronary) * end of procedure (start of vascular closure) * time until wire placed in distal coronary bed for purpose of intervention * time of first stent placement

Outcome measures

Outcome measures
Measure
PCI Phase 1
n=24 Participants
Phase 1 subject undergoing a percutaneous coronary intervention with navigation support of Dynamic Coronary Roadmap
PCI Phase 2
Not initiated.
Procedure Efficiency
The time from start of the procedure until end of the procedure
46.5 minutes
Standard Deviation 49.71
Procedure Efficiency
The time from start of the procedure until first stent is placed
24 minutes
Standard Deviation 19.79

OTHER_PRE_SPECIFIED outcome

Timeframe: Amount [number] will be determined once, at the end of the Percutaneous Coronary Intervention. There is no patient follow-up.

Population: No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

Is used as a metric for procedural complexity.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Quality [score] will be determined once, at the end of the Percutaneous Coronary Intervention. There is no patient follow-up.

Population: No data gathered for the primary outcome. Phase 2 not initiated Only phase 1 data was collected

The operating physician is asked after the procedure to indicate what the quality and clinical usefulness of those images by scoring on a 5-point rating scale.

Outcome measures

Outcome data not reported

Adverse Events

PCI Phase 1

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pim van Lochem

Philips Medical Systems B.V.

Phone: +31 (0)634322891

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place